NCT03994913: Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma |
|
|
| Completed | 1/2 | 20 | RoW | CAR-CD19 T Cells | CARsgen Therapeutics Co., Ltd., First Affiliated Hospital of Zhejiang University, RenJi Hospital | Refractory B-Cell Non-Hodgkin Lymphoma, Relapsed B-cell Non-Hodgkin Lymphoma | 01/21 | 05/21 | | |
| Recruiting | N/A | 45 | | N/A | Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine, CARsgen Therapeutics, Ltd. | CD19+ Malignant Leukemia and Lymphoma | | | | |
NCT03302403: Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors |
|
|
| Active, not recruiting | N/A | 18 | RoW | CAR-CD19 T cell, CD19-redirected Autologous Cell, CAR-BCMA T cell, BCMA-redirected Autologous Cell, CAR-GPC3 T cell, GPC3-redirected Autologous Cell, CAR-CLD18 T cell, Claudin18.2-redirected Autologous Cell, Fludarabine, Cyclophosphamide | Kang YU, CARsgen Therapeutics Co., Ltd. | B Cell Lymphoma, B Cell Leukemia, Myeloma, Hepatocellular Carcinoma, Pancreatic Carcinoma, Adenocarcinoma of Esophagogastric Junction | 12/20 | 12/23 | | |
